Boston Scientific Taxus Stent News

WSJ Report on Stent Blood Clots Refuted

At a glance:

Contrary to a report in the Wall Street Journal, officials at Angiotech, a company that makes drug preparations for stents, say that the use of drug-coated stents is not declining and that they remain more effective than bare metal stents. 
 
The Journal report had stated that hospitals were concerned about the formation of blood clots so had begun to avoid stents such as Boston Scientific Taxus Stent. 
 
As Angiotech's stock price declined, its President also declared that it was looking to widen its business and reduce the percentage of revenue coming from that source. 
 


Angiotech shares drop on report of lower stent use

Reuters - 6/22/2006 1:45 PM

TORONTO (Reuters) - Shares of Angiotech Pharmaceuticals fell more than 6 percent on Thursday after the Wall Street Journal reported a decline in the use of drug-coated stents at several major hospitals.
 
Shares of Angiotech, whose main revenue has come from making a drug coating for Boston Scientific's stents, were down 69 Canadian cents, or 4.9 percent, at C$13.40 on volume of 159,000 shares. Earlier in the session, they dropped as low as C$13.15

 
· Read The Full Boston Scientific Taxus Stent Article From Reuters -->

· Read All Boston Scientific Taxus Stent News Stories -->

Comments On Boston Scientific Taxus Stent News Articles:


No Current Comments
Posted by Admin on 3/20/2006

There are no current comments. Why not post one?

Leave a Comment:

Once you click the 'Save Comment' button, you will receive a verification email from our website. Be sure to change any spam settings to allow webmaster@lawsuitsearch.com as a trusted sender.
 
If you are already a member, you can Sign In Here.
 
You can create your own FREE user account that you can use to participate in our message boards, blogs, newsletters and other community activities such as this one. To get your FREE user account, click here.

Email Address:

Your Name:

Message Title:

Message: